Loading...
Tumor treating fields (TTF) is a noninvasive therapy that uses alternating low-intensity electric fields to inhibit cancer cell proliferation. Now, investigators report treatment outcomes in patients with locally advanced unresectable pancreatic adenocarcinoma who received gemcitabine and nab-paclitaxel with or without TTF in an industry-sponsored, open-label phase 3 global trial. Of the 571 participants, most had tumors of the pancreatic head (51%) or body (28%). Nearly half (43%) received treatment in North America, 58% were ECOG PS 1, and only 4% were ECOG 2.
Overall survival (OS) was significantly lengthened with the addition of TTF to chemotherapy over chemotherapy alone (median, 16.2 months vs. 14.2 months; hazard ratio, 0.82), with no…